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Abstract
Melanoma, the deadliest form of skin cancer, is caused primarily by exposure to ultraviolet radiation. Tumor formation
occurs early in disease progression and can easily metastasize. The development of the disease can be described by one
of four stages, characterized by tumor size and risk of spreading. The B-rafprotein plays an important role in cell proliferation and has the ability to develop a mutation for continuous
activation, resulting in uncontrolled cell growth. Sixty percent
of melanomas possess a V600E mutation in the BRAF gene.
Recently, drug developers have turned the focus of melanoma
treatments toward preventing the activation of the mitogenactivated protein kinase (MAPK) pathway and, consequently,
cell proliferation is decreased and leads to cell cycle arrest.
Two of the newest U.S. Food and Drug Administration (FDA)approved medications for the treatment of melanoma are
trametinib (Mekinist®) and dabrafenib (Taflinar®). It is
important for pharmacists to understand the benefits, side
effects and potential warnings involved with trametinib and
dabrafenib so they are better able to educate their patients on
these innovations in melanoma treatment.
Introduction
Melanoma causes the greatest fatality rates among skin diseases, even though it is not as prevalent as other skin cancers,1.2 Approximately 76,000 individuals in the United States
were predicted to be newly diagnosed with melanoma in
2013, and about 48,000 deaths occur each year worldwide.3.4
Melanoma is caused primarily by environmental factors,
such as ultraviolet radiation from the sun or tanning beds,
but the risk of developing melanoma can also be increased by
genetic mutations, as will be discussed. Exposure to ultraviolet light may damage deoxyribonucleic acid (DNA) of skin
cells, especially melanocytes, leading to mutations resulting
in uncontrolled cell growth and tumor formation. This is potentially fatal for patients, especially if cancer cells metastasize to other areas of the body.
Identifying early signs of melanoma is a major step to halt
the spreading and prevent the progression of cancer into
irreversible stages. According to the American Cancer Society, a mnemonic device of ABCDE is employed to identify
warning signs in skin growths or moles in both clinical practice and home examinations. "A" stands for asymmetry of the
mole, "B" for borders due to the jagged edges, "C" for color
and any changes in color within one area, "D'' for diameter of
greater than six millimeters (mm) and "E" for evolution of
the mole's shape or change in appearance. If detected early in
disease progression, the suspected growths of cancerous
melanocytes can be surgically removed via biopsy without
complications.s
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The guide used for staging melanoma is classified by
Breslow's thickness, defined as thickness of the tumor and its
depth of penetration into the skin. Although many sub-stages
have been identified, a simplified guide consists of four
stages characterized by tumor size with an additional "stage
O" defining an in situ, non-invasive small tumor on the skin
surface. Stage I features invasive tumors less than one mm
thick Stage II tumors are between one and two mm thick,
may be considered invasive, and generally feature local ulcerations allowing for greater risk of metastasis. Stages lII
and IV possess tumors with sizes between two mm to four
mm and greater than four mm, respectively, but tumor size
in these stages is less relevant due to the potential complications of metastasis. According to the American Cancer Society, five year survival rates of stages I and II are between SO
and 90 percent, stage lII ranges from 40 to 78 percent and
late-stage, stage IV a mere 15 to 20 percent rate.s Skin biopsies are no longer sufficient in the spreading stages and adjuvant therapy with anticancer drugs is required.

Current Melanoma Drug Therapy
There are few medications that have been approved and
used for treatment of late-stage melanoma. Prior to 2006, the
only FDA-approved drug for use in melanoma was dacarbazine (DTIC®), a DNA-alkylating prodrug. It shares many similarities with temozolomide (Temodar®), which is commonly
used for late-stage metastatic melanoma. However, temozolomide is only indicated for treatment of two specific astrocytoma-induced brain tumors and is not FDA-approved
for melanoma. In 2011, two new drugs gained approval for
melanoma, ipilimumab (Yervoy®) and vemurafenib (Zelboraf®).
Ipilimumab, a monoclonal antibody, acts by preventing the
inhibition of cytotoxic T-lymphocytes thus allowing them to
identify and destroy the rapidly dividing cancerous melanocytes. Mutations in the 8-raf protein have been associated
with tumor development, specifically melanomas that are
driven by point mutations in the 8RAF gene known as V600E
and V600K, which occur in 60 percent and 10 percent of
melanomas, respectively.6 Vemurafenib specifically inhibits
the kinase activity of V600E and V600K forms of 8-raf, with
little activity against the wild-type form. While highly effective, this drug is only useful if the patient has one of the
above mutations. To understand the beneficial effects of vemurafenib, an appreciation of 8-raf in melanoma is required.7
In non-malignant cells, 8-raf is a key player in the mitogenactivated protein kinase (MAPK) pathway as shown in Figure
1. Typically, following activation of a membrane-located tyrosine kinase receptor or G protein-coupled receptor, second
messenger molecules are generated and intracellular signal-
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ing proteins are activated. In several cell types, these events
lead to activation of 8-raf. 8-raf, a serine/threonine kinase,
activates mitogen-activated extracellular kinase (MEK) that
in turn stimulates extracellular signal-regulated kinase
(ERK). Signaling via this pathway leads to activation of gene
transcription resulting in several functional effects including
increased cell proliferation and survival. Conversely, mutated 8-raf (e.g. 8RAF V600E) will signal in an unregulated
fashion leading to constant activation of the MAPK pathway.
Cancerous melanocytes may develop due to this dysregulated signaling and inability of the cell to respond to feedback
inhibition that ultimately leads to increased cell proliferation
and survivaJ.8
New Melanoma Drug Therapy
The development of selective 8-raf inhibitors for the treatment of malignancies caused by V600E and V600K mutations
represents the first successful application of targeted therapy in melanoma. A clinical challenge with the available 8-raf
inhibitors is that cancerous melanocytes are able to develop
cross-resistance to selective 8-raf inhibition through a
mechanism whereby the cell switches the isoform of the Raf
kinase protein employed for proliferation. Trametinib
(Mekinist®) and dabrafenib (Tafinlar®) are recently developed inhibitors of the MAPK pathway and are alternative
therapies that may decrease the likelihood of resistance de-
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veloping to 8-raf inhibition therapy. Specifically, dabrafenib
is the most recently introduced 8-raf inhibitor, while
trametinib is a MEK inhibitor.9 Although trametinib and
dabrafenib are not the first inhibitors of this pathway on the
market, both drugs are easier for patients to self-manage and
are available in once (dabrafenib) and twice (trametinib)
daily oral dosing. The cost of these drugs is also relatively
lower compared to a $13,021 30-day supply ofvemurafenib.
Trametinib and dabrafenib monthly costs summate to
$10,440 and $9,120 respectively, significantly lower than
that of vemurafenibJO,ll It has also been shown that exclusive therapy with dabrafenib reduces the absolute risk of
squamous cell carcinoma by 22 percent compared to vemurafenib, and shrinkage of tumors was also found in nine of 10
patients,tz,13 Squamous cell carcinoma risk was found to be
non-existent in a phase II trial of trametinib. It is evident
these two new entities show increased benefits compared to
previous MAPK pathway inhibitors.9
Dabrafenib
Dabrafenib (Tafinlar®) was approved by the FDA on May 29,
2013, as a treatment for patients with 8RAF V600E mutations in unresectable or metastatic melanoma. However, it is
not indicated for patients with wild-type 8-raf melanoma
because of a potential increase in tumor formation.14 Dabrafenib selectively inhibits the 8RAF V600E mutation which, as

Figure 1. Schematic Representation ofB-rafand MEK Signaling in Melanoma. 8

Dabrafenib

Profiferation

Survivaf
Certain proteins have been omitted for simplicity in identifying drug targets. Please see text for abbreviations and details
of signaling cascade and functional responses. BRAF V600E represents B-raf in which valine at position 600 has been
mutated to glutamic acid with a resulting constitutive signaling activity. BRAF V600E may drive the melanoma
phenotype and is the specific target of dabrafenib. MEK is activated downstream of B-RAF V600E and stimulates ERK
Trametinib is an inhibitor of the kinase activity of MEK
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described previously, is responsible for constitutive activity
of the MAPK pathway and initiating uncontrolled cell proliferation. Blockade of this pathway results in inhibition of tumor cell growth and discontinuation of cancer progression.11
Dabrafenib is administered orally, twice daily, in lSO mg
doses until disease progression or undesirable toxicity occurs. Recommended dose adjustments for toxicity include:
first dose reduction of 100 mg twice daily, second dose reduction of 7S mg twice daily, and third dose reduction of SO
mg twice daily. If the patient is unable to tolerate SO mg
twice daily, dabrafenib should be discontinued. Doses should
be taken at least one hour before, or two hours after, a meal.
Missed doses may be administered up to six hours prior to
the next dose. If less than six hours remain until the next
scheduled dose, do not administer.11
It is important that the patient is made aware of possible adverse effects prior to the initiation of treatment with dabrafenib. The most common adverse reactions (~ 20 percent incidence) are hyperkeratosis, headache, pyrexia, arthralgia,
papilloma, alopecia, and palmar-plantar erythrodysesthesia
syndrome.1 4 Labeled warnings that should be discussed with
the patient are febrile drug reactions, such as fever, chills,
and dehydration. Dabrafenib is categorized as a pregnancy
risk factor D drug. Females who are pregnant or may become
pregnant should not take dabrafenib. Adverse effects were
observed in animal studies, and based on the mechanism of
action, fetal harm can be expected if dabrafenib is administered to pregnant women due to a potential decrease in the
serum concentration of estrogens and progestins. Females
with high reproductive potential throughout the course of
therapy and four weeks beyond the termination of therapy
should use non-hormonal contraceptives. Breast-feeding is
not recommended during dabrafenib therapy. Impaired spermatogenesis may also be experienced in males. No dosing
adjustments are necessary for mild to moderate renal impairment or mild hepatic impairment. Severe renal impairment and moderate to severe hepatic impairment effects
have not been studied. There are no special geriatric considerations for this drug and there is no pediatric dosing information listed. There are also no listed contraindications of
dabrafenib with other medications.11
The decision for the approval of dabrafenib was based on
improved progression-free survival (PFS) by treatment with
dabrafenib over chemotherapy, as demonstrated in a randomized (3:1) active-controlled trial. The trial enrolled 2SO
patients with previously untreated stage III or stage IV melanoma with the BRAF V600E mutation. Participants were randomized to receive either oral dabrafenib lSO mg twice daily
(n=l87) or dacarbazine 1000 mg/m2 intravenously once
every three weeks (n=63). Sixty percent of the participants
were males and the median age was S2 years. A statistically
significant PFS was observed in patients receiving dabrafenib
therapy (hazard ratio [HR] 0.33, 9S percent confidence interval [CI]: 0.20, 0.54; p<0.0001). The median PFS rates were
S.l months and 2.7 months in treatment with dabrafenib and
dacarbazine, respectively. These data suggest that prolongation of PFS can be obtained by using dabrafenib as a metas-
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tatic melanoma treatment.14
Trametinib
On May 29, 2013, the FDA approved trametinib (Mekinist®)
for the treatment of cancer patients with unresectable or
metastatic melanoma with BRAF V600E or V600K mutations.13 Trametinib selectively and reversibly inhibits MEK 1
and MEK 2 kinase activity. As described previously, MEK is
the subsequent effector of B-raf in the cell proliferation pathway. By inhibiting the activation of MEK 1 and MEK 2,
trametinib decreases cellular proliferation, promotes cell
cycle arrest, and increases apoptosis of tumor cells.10 The
recommended dose for trametinib is 2 mg once daily by oral
route until disease progression or toxicity is identified. If
cardiac toxicity, including 10 percent decrease in left ventricular ejection fraction (LVEF) from baseline occurs, it is
suggested to interrupt therapy for up to four weeks, then, if
LVEF improves to normal, decrease the dose by 0.5 mg. If
there is greater than a 20 percent decrease in LVEF, or symptomatic heart failure occurs, discontinue trametinib permanently. If a grade 2 dermatologic rash develops, decrease the
dose by O.S mg; but if only taking 1 mg daily, discontinue use.
If the grade 2 rash does not improve within three weeks of
decreasing the dose, or a grade 3 or grade 4 rash develops,
interrupt therapy for up to three weeks. If improvement still
does not occur after three weeks, discontinue therapy. If
grade 2 or 3 retinal pigment epithelial detachments (RPED)
occur, interrupt therapy up to three weeks. If RPED improves
after three weeks, resume therapy by decreasing the dose by
0.5 mg. If RPED does not improve, discontinue use.
Trametinib should be administered at least one hour before,
or two hours after, a meal. Missed doses should not be taken
within 12 hours of the next dose.10
As trametinib is a new treatment option, it is important to
educate patients on the possible adverse side effects of the
medication when initiating treatment. The most common
side effects c~ 20 percent incidence) include rash, diarrhea
and lymphedema.1s There are no listed contraindications for
trametinib with other drugs. Dosage adjustments are not
necessary in cases of mild to moderate renal impairment or
mild hepatic impairment. Adjustments for severe renal impairment and moderate to severe hepatic impairment have
not been defined. Possible adverse events include cardiomyopathy, dermatologic toxicity, ocular complications such
as RPED or retinal vein occlusion and pulmonary toxicity.
Trametinib is categorized as a pregnancy risk factor D drug.
Women who are pregnant or trying to conceive should not
take trametinib. No clinical studies have been conducted on
pregnant women, but based on the mechanism of action it
can be inferred that the medication could cause fetal harm as
well as impair fertility. There are no special geriatric considerations to keep in mind, and no information is listed for pediatric dosing considerations.10
Recent studies have demonstrated positive responses to
trametinib in the treatment of melanoma. The decision to
approve trametinib as a melanoma therapy was based on
results of increased PFS when compared to chemotherapy.1s
In a phase III randomized active-controlled trial conducted

THE PHARMACY AND WELLNESS REVIEW

June 2014 Volume 5, Issue 2

Trametinib and Dabrafenib: New Agents for Advanced Stage Melanoma

by Flaherty et al., 322 patients with mutation positive metastatic melanoma were assigned to receive either trametinib or
chemotherapy in a 2:1 ratio. Patients in the experimental
group (n=214) received trametinib 2 mg once daily, and the
patients in the chemotherapy group (n=108) received intravenous dacarbazine (1000 mg/m2) or paclitaxel (175 mg/
mZ) every three weeks. Treatment continued until disease
progression was observed, death, or withdrawal from the
study. Patients in the chemotherapy group that experienced
disease progression were allowed to change therapies to
trametinib. The median PFS with trametinib was 4.8 months
and 1.5 months with chemotherapy ([HR] for disease progression/death in trametinib cohort, 0.45; 95 percent [CI],
0.33 to 0.63; p<0.001). The overall survival rate at six
months was 81 percent with trametinib and 67 percent with
chemotherapy.9
In addition to the study conducted by Flaherty et al. that investigated the benefits of choosing trametinib over traditional chemotherapy, other trials have been conducted to
further specify the population for which trametinib should
be indicated. In 2012, Kim et al. published a phase II clinical
trial studying the effects of trametinib in patients with metastatic BRAF-mutant cutaneous melanoma that had been
previously treated with or without a BRAF inhibitor.16 Participants were divided into two groups. Participants in cohort A were previously treated with a BRAF inhibitor, while
those in cohort 8 had received chemotherapy and/or immunotherapy treatment prior to the study. Both groups were
administered oral daily doses of trametinib 2 mg. Results of
the study indicated that the median PFS in cohort A was 1.8
months, whereas the PFS in cohort B was four months. 16
These results confirm that trametinib had a better clinical
impact on patients without previous treatment with BRAF
inhibitors than those who had received BRAF inhibition
treatment. These data suggest that BRAF inhibitor resistance
mechanisms may also have an effect on MEK inhibition therapy, and therefore it should be noted that trametinib is not
indicated for use in patients who have received prior treatment with BRAF inhibitors.is
Conclusion
Since detecting melanoma in its early stages is key to increasing duration and quality of life in patients, the pharmacist
needs to have the ability to recognize possible skin irregularities on patients and be able to refer them to their primary
care physician or dermatologist. Pharmacists must also be
able to provide basic counseling information for trametinib
and dabrafenib because these drugs may cause severe side
effects, especially when taken incorrectly. Pharmacies may
see trametinib and dabrafenib on their shelves relatively
soon due to the prevalence of melanoma in the population
and the availability of these drugs as an oral dosage form.
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tivity in targeting cells that contain a certain mutation in the
BRAF gene. More studies need to be done on genetic expression of melanoma cancer cells in order to increase the chance
of finding more mutations or pathways to target with drugs.
Furthermore, studies need to further evaluate dabrafenib
and trametinib in order to establish more confidence of the
safety and efficacy of these medications.
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Melanoma is a severe type of skin cancer due to its high mortality rates in the metastatic stages of the cancer. Fortunately,
two drugs, trametinib and dabrafenib, have recently been
approved by the FDA to combat metastatic melanoma and
improve the length and quality of life in patients. These
newly approved medications are effective due to their selecJune 2014 Volume 5, Issue 2
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